|
1
|
Villanueva A: Hepatocellular carcinoma. N
Engl J Med. 380:1450–1462. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Korean Liver Cancer Association (KLCA) and
National Cancer Center (NCC) Korea, . 2022 KLCA-NCC Korea practice
guidelines for the management of hepatocellular carcinoma. J Liver
Cancer. 23:1–120. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kudo M, Finn RS, Qin S, Han KH, Ikeda K,
Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib
versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: A randomised phase 3
non-inferiority trial. Lancet. 391:1163–1173. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marisi G, Cucchetti A, Ulivi P, Canale M,
Cabibbo G, Solaini L, Foschi FG, De Matteis S, Ercolani G,
Valgiusti M, et al: Ten years of sorafenib in hepatocellular
carcinoma: Are there any predictive and/or prognostic markers?
World J Gastroenterol. 24:4152–4163. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab
plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J
Med. 382:1894–1905. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Han JW and Jang JW: Predicting outcomes of
atezolizumab and bevacizumab treatment in patients with
hepatocellular carcinoma. Int J Mol Sci. 24:117992023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Han JW and Yoon SK: Immune responses
following locoregional treatment for hepatocellular carcinoma:
Possible roles of adjuvant immunotherapy. Pharmaceutics.
13:13872021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sprinzl MF, Reisinger F, Puschnik A,
Ringelhan M, Ackermann K, Hartmann D, Schiemann M, Weinmann A,
Galle PR, Schuchmann M, et al: Sorafenib perpetuates cellular
anticancer effector functions by modulating the crosstalk between
macrophages and natural killer cells. Hepatology. 57:2358–2368.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kato Y, Tabata K, Kimura T,
Yachie-Kinoshita A, Ozawa Y, Yamada K, Ito J, Tachino S, Hori Y,
Matsuki M, et al: Lenvatinib plus anti-PD-1 antibody combination
treatment activates CD8+ T cells through reduction of
tumor-associated macrophage and activation of the interferon
pathway. PLoS One. 14:e02125132019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hernandez-Gea V, Toffanin S, Friedman SL
and Llovet JM: Role of the microenvironment in the pathogenesis and
treatment of hepatocellular carcinoma. Gastroenterology.
144:512–527. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen R, Li Q, Xu S, Ye C, Tian T, Jiang Q,
Shan J and Ruan J: Modulation of the tumour microenvironment in
hepatocellular carcinoma by tyrosine kinase inhibitors: From
modulation to combination therapy targeting the microenvironment.
Cancer Cell Int. 22:732022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sunay MME, Foote JB, Leatherman JM,
Edwards JP, Armstrong TD, Nirschl CJ, Hicks J and Emens LA:
Sorafenib combined with HER-2 targeted vaccination can promote
effective T cell immunity in vivo. Int Immunopharmacol. 46:112–123.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yi C, Chen L, Lin Z, Liu L, Shao W, Zhang
R, Lin J, Zhang J, Zhu W, Jia H, et al: Lenvatinib targets FGF
receptor 4 to enhance antitumor immune response of anti-programmed
cell death-1 in HCC. Hepatology. 74:2544–2560. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang Y, Chen D, Zhao B, Ren L, Huang R,
Feng B and Chen H: The predictive value of PD-L1 expression in
patients with advanced hepatocellular carcinoma treated with
PD-1/PD-L1 inhibitors: A systematic review and meta-analysis.
Cancer Med. 12:9282–9292. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tischfield DJ, Gurevich A, Johnson O,
Gatmaytan I, Nadolski GJ, Soulen MC, Kaplan DE, Furth E, Hunt SJ
and Gade TPF: Transarterial embolization modulates the immune
response within target and nontarget hepatocellular carcinomas in a
rat model. Radiology. 303:215–225. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Marrero JA, Kulik LM, Sirlin CB, Zhu AX,
Finn RS, Abecassis MM, Roberts LR and Heimbach JK: Diagnosis,
staging, and management of hepatocellular carcinoma: 2018 Practice
guidance by the American association for the study of liver
diseases. Hepatology. 68:723–750. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Korean Liver Cancer Association (KLCA) and
National Cancer Center (NCC) Korea, . 2022 KLCA-NCC Korea practice
guidelines for the management of hepatocellular carcinoma. Clin Mol
Hepatol. 28:583–705. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Paver EC, Cooper WA, Colebatch AJ,
Ferguson PM, Hill SK, Lum T, Shin JS, O'Toole S, Anderson L,
Scolyer RA and Gupta R: Programmed death ligand-1 (PD-L1) as a
predictive marker for immunotherapy in solid tumours: A guide to
immunohistochemistry implementation and interpretation. Pathology.
53:141–156. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sangro B, Melero I, Wadhawan S, Finn RS,
Abou-Alfa GK, Cheng AL, Yau T, Furuse J, Park JW and Boyd Z:
Association of inflammatory biomarkers with clinical outcomes in
nivolumab-treated patients with advanced hepatocellular carcinoma.
J Hepatol. 73:1460–1469. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Llovet JM and Lencioni R: mRECIST for HCC:
Performance and novel refinements. J Hepatol. 72:288–306. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Reig M, Forner A, Rimola J, Ferrer-Fàbrega
J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V,
Salem R, et al: BCLC strategy for prognosis prediction and
treatment recommendation: The 2022 update. J Hepatol. 76:681–693.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Song MJ: Hepatic artery infusion
chemotherapy for advanced hepatocellular carcinoma. World J
Gastroenterol. 21:3843–3849. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Breedis C and Young G: The blood supply of
neoplasms in the liver. Am J Pathol. 30:969–977. 1954.PubMed/NCBI
|
|
25
|
Torimura T and Iwamoto H: Optimizing the
management of intermediate-stage hepatocellular carcinoma: Current
trends and prospects. Clin Mol Hepatol. 27:236–245. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
He MK, Le Y, Li QJ, Yu ZS, Li SH, Wei W,
Guo RP and Shi M: Hepatic artery infusion chemotherapy using
mFOLFOX versus transarterial chemoembolization for massive
unresectable hepatocellular carcinoma: A prospective non-randomized
study. Chin J Cancer. 36:832017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Song DS, Song MJ, Bae SH, Chung WJ, Jang
JY, Kim YS, Lee SH, Park JY, Yim HJ, Cho SB, et al: A comparative
study between sorafenib and hepatic arterial infusion chemotherapy
for advanced hepatocellular carcinoma with portal vein tumor
thrombosis. J Gastroenterol. 50:445–454. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sung PS, Yang K, Bae SH, Oh JS, Chun HJ,
Nam HC, Jang JW, Choi JY and Yoon SK: Reduction of intrahepatic
tumour by hepatic arterial infusion chemotherapy prolongs survival
in hepatocellular carcinoma. Anticancer Res. 39:3909–3916. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee J, Han JW, Sung PS, Lee SK, Yang H,
Nam HC, Yoo SH, Lee HL, Kim HY, Lee SW, et al: Comparative analysis
of lenvatinib and hepatic arterial infusion chemotherapy in
unresectable hepatocellular carcinoma: A multi-center, propensity
score study. J Clin Med. 10:40452021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chan LL and Chan SL: The evolving role of
lenvatinib at the new era of first-line hepatocellular carcinoma
treatment. Clin Mol Hepatol. 29:909–923. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee MMP, Chan LL and Chan SL: The role of
lenvatinib in the era of immunotherapy of hepatocellular carcinoma.
J Liver Cancer. 23:262–271. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim JH, Nam HC, Kim CW, Cho HS, Yoo JS,
Han JW, Jang JW, Choi JY, Yoon SK, Yang H, et al: Comparative
analysis of atezolizumab plus bevacizumab and hepatic artery
infusion chemotherapy in unresectable hepatocellular carcinoma: A
multicenter, propensity score study. Cancers (Basel). 15:42332023.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Iwamoto H, Shimose S, Shirono T, Niizeki T
and Kawaguchi T: Hepatic arterial infusion chemotherapy for
advanced hepatocellular carcinoma in the era of chemo-diversity.
Clin Mol Hepatol. 29:593–604. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Greten TF, Mauda-Havakuk M, Heinrich B,
Korangy F and Wood BJ: Combined locoregional-immunotherapy for
liver cancer. J Hepatol. 70:999–1007. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhu AX, Finn RS, Edeline J, Cattan S,
Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A,
et al: Pembrolizumab in patients with advanced hepatocellular
carcinoma previously treated with sorafenib (KEYNOTE-224): A
non-randomised, open-label phase 2 trial. Lancet Oncol. 19:940–952.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cheng AL, Qin S, Ikeda M, Galle PR,
Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, et al:
Updated efficacy and safety data from IMbrave150: Atezolizumab plus
bevacizumab vs sorafenib for unresectable hepatocellular carcinoma.
J Hepatol. 76:862–873. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yau T, Kang YK, Kim TY, El-Khoueiry AB,
Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, et al:
Efficacy and safety of nivolumab plus ipilimumab in patients with
advanced hepatocellular carcinoma previously treated with
sorafenib: The CheckMate 040 randomized clinical trial. JAMA Oncol.
6:e2045642020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yamazaki T, Akiba H, Iwai H, Matsuda H,
Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, et al:
Expression of programmed death 1 ligands by murine T cells and APC.
J Immunol. 169:5538–5545. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Calderaro J, Rousseau B, Amaddeo G, Mercey
M, Charpy C, Costentin C, Luciani A, Zafrani ES, Laurent A, Azoulay
D, et al: Programmed death ligand 1 expression in hepatocellular
carcinoma: Relationship With clinical and pathological features.
Hepatology. 64:2038–2046. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sung PS: Crosstalk between
tumor-associated macrophages and neighboring cells in
hepatocellular carcinoma. Clin Mol Hepatol. 28:333–350. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Park JG, Roh PR, Kang MW, Cho SW, Hwangbo
S, Jung HD, Kim HU, Kim JH, Yoo JS, Han JW, et al: Intrahepatic IgA
complex induces polarization of cancer-associated fibroblasts to
matrix phenotypes in the tumor microenvironment of HCC. Hepatology.
Feb 15–2024.(Epub ahead of print). View Article : Google Scholar
|
